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Poster Session II S339(95% CI 16 – 44%) by one year. The cumulative incidence of pri-
mary disease relapse was 23% (95% CI 13 – 41%) at 1 year. CMV
reactivation differed according to recipient and donor CMV
serostatus. EBV reactivation occurred in 54% (95% CI 40% -
71%). Preemptive rituximab therapy controlled EBV in the majority
of cases; however, PTLD was diagnosed in 5 cases, and was fatal in
one. A regimen of ATG 7.5mg/kg today ending on day -1 effectively
prevents grade III-IV acute GVHD and severe chronic GVHD in
6-7/8 mismatched unrelated donor HCT.519
INFLUENCE OF GENOMIC STRUCTURAL VARIANTS ON GVHD AND RE-
LAPSE RISK IN LYMPHOMA PATIENTS TREATED WITH ALLOGENEIC
HSCT
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Copy number variants (CNV) contribute to the risk of multiple
common diseases and are implicated in unfavorable clinical out-
comes in HSCT. The role of CNVs bearing immuno-tolerance
genes (mHAg) has been demonstrated for UGT2B17 in HLA-
matched siblings after HSCT (McCarroll, et alNat Genet 2009). Ho-
mozygous CNV deletion trans€ıplant donors mismatched with
CNV+ recipients may harbor immune systems na€ıve to proteins
present within the recipient eliciting GVHD demonstrating a grow-
ing role for CNVs in transplant medicine. Allogeneic HSCT, a po-
tentially curative therapy for recurrent non-Hodgkin lymphoma
(NHL), is often compromised by transplant-mediated GVHD
thereby jeopardizing patient survival. Owing to known differences
in CNV allele frequencies in ethnically diverse populations com-
bined with the racially diverse composition of NHL patients seen
at our institution, the incidence of CNV-mediated GVHD may
very widely. To test this premise, we are examining the affect of pop-
ulation-specific CNVs on GVHD in a cohort of NHL patients.
We are investigating GVHD in 292 patients who underwent
HSCT to 1) determine the genetic admixture of our patients, 2) sub-
sequently use genetic ancestry to guide the selection of CNVs for
GVHD association testing, and 3) develop a novel mass spectrome-
try based platform to genotype CNVs. In our initial group of 85 pa-
tients who underwent allo-HSCT (64 related and 21 unrelated
donors), grade II-IV acute GVHD occurred in 43 patients, and 21
experienced NHL relapse. Forty-eight patients self-reported as
non-Hispanic Caucasian, 3 African American, 5 Asian, and 29 His-
panic or Latino. Genetic admixture estimates with a panel of 100
Ancestry Informative Markers were used to define genetic ancestry
and correlate to self-reported ethnicity. Admixture analysis on self-
reported Hispanics showed that 69% (20/29) contained. 10% Am-
erIndian ancestry. Weighted ancestry estimates in 3 HapMap popu-
lations based on genetic proportions observed in our patients
indicate numerous CNV alleles as potential targets, 48 of these
have allele frequencies . 10% in our cohort and represent possible
targets for donor-recipient mismatches.
We are genotyping donor/recipient pairs for a select group of
CNVs in conjunction with UGT2B17 using mass spectroscopy to
correlate CNV discordant pairs with GVHD. Approaches like this
are applicable to the racially diverse patient populations commonly
seen at institutions performing HSCT and may improve clinical
outcomes.520
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Introduction: Efficacy of donor lymphocyte infusion (DLI) for
relapsed acute leukemia after allogeneic hematopoietic cell trans-
plantation (HCT) is limited. We hypothesized that interleukin-2
(IL-2) combined with DLI after chemotherapy might augmentgraft-versus-leukemia effects. To identify a safe and effective IL-2
regimen, a phase I/II study of DLI plus IL-2 therapy was performed.
Methods: Patients with relapsed acute myeloid leukemia (AML) or
acute lymphoblastic leukemia (ALL) after allogeneic HCT were el-
igible for this study. After chemotherapy, patients received DLI
(1x108 CD3/kg for patients with related donors, and 0.1x108 CD3/
kg for those with unrelated donors) and an escalating dose of induc-
tion IL-2 (Aldesleukin, Chiron, CA; 1.0, 2.0, or 3.0x106 IU/m2/day
representing levels I, Ia and II) for 5 days followed by maintenance
(1.0x106 IU/m2/day) for 10 days as a continuous intravenous infu-
sion. Study toxicities were prespecified. An excess study toxicity
rate was defined as any incidence where the lower limit of the 80%
one-sided confidence interval exceeded 25%. To examine the poten-
tial efficacy of this therapy, disease-free survival (DFS) was estimated
according to diagnosis and remission status at time of DLI.
Results:Atotalof17patients(11withAMLand6withALL)withmedian
age33years(range19-61)wereenrolledinthisstudy.Donorswererelated
siblingsfor13patientsandunrelatedvolunteersfor4patients.Sixteenpa-
tientshadapriorhistoryofGVHD.ThemediantimefromHCTtoche-
motherapy was 11.8 months (range 3-121). The median time from
chemotherapytoDLIwas61days(range36-91).Outcomesaresumma-
rizedintheTable.IL-2relatedtoxicitieswerereversibleinallexceptin1
patientatlevelIIwhodiedofcapillaryleaksyndrome.GradesIII-IVacute
GVHDdevelopedin5patients,andextensivechronicGVHDdeveloped
in8.Studytoxicitiesdevelopedin1patientatIL-2doselevelI,2patientsat
levelIaand1patientat levelII.Eightpatientshadacompleteremission
afterchemotherapypriortoDLI,and2additionalpatientshadacomplete
remissionafterDLIplusIL-2therapy.DFSat1yearwas40%forpatients
withAMLincomplete remissionatDLI (n55) and8%for thosewith
AMLnotinremission(n56)orALLinanystageatDLI(n56).
Conclusion: The maximal tolerated induction dose of IL-2 com-
bined with DLI appears to be 1.0x106 IU/m2/day. IL-2 administra-
tion after DLI might increase the incidence of chronic GVHD.
Table 1. GVHD, study toxicity and remission duration after
DLI according to IL-2 dose level
RemissionPatient# DiagnosisIL-2 Dose
LevelAcute
GVHDChronic
GVHDStudy
Toxicity*Duration after
DLI (Month)1 AML I 0 NA N 02 AML I III Extensive N 333 AML I III Extensive N 354 AML I 0 Extensive N 05 ALL I 0 0 N 06 ALL I III Extensive Y (GVHD) 87 ALL I 0 0 N 58 AML Ia 0 NA N 09 AML Ia 0 0 N 010 AML Ia II Extensive N 911 AML Ia 0 Extensive N 512 AML Ia IV Extensive Y (GVHD) 4713 AML Ia 0 0 N 614 AML Ia 0 0 N 315 ALL Ia 0 Limited N 016 ALL Ia III Extensive Y (IL-2) 1217 ALL II 0 NA Y (IL-2) 0*Death related to acute or chronic GVHD, development of acute or
chronic GVHD with inability to decrease the dose of prednisone to
less than 1mg/kg/day within 1 month after initiating treatment for
GVHD, or life threatening or fatal organ toxicity attributable to IL-2.521
INTERFERON-GAMMA PRODUCTION BY ALLOGENEIC FOXP3+ REGULA-
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Background and Aims:Adoptive transfer of natural FoxP3+ regula-
tory T cells (Tregs) has been shown to prevent lethal GvHD. It is
emerging that Tregs are a stable lineage that do not revert into harm-
ful FoxP3 effector cells. However, we have recently found that Tregs
